U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H17N2O3.Na
Molecular Weight 248.254
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMOBARBITAL SODIUM

SMILES

[Na+].CCC1(CCC(C)C)C(=O)NC(=O)[N-]C1=O

InChI

InChIKey=BNHGKKNINBGEQL-UHFFFAOYSA-M
InChI=1S/C11H18N2O3.Na/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15;/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C11H18N2O3
Molecular Weight 226.2722
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

AMOBARBITAL is a barbiturate derivative with hypnotic and sedative properties. In an in vitro study in rat thalamic slices amobarbital worked by activating GABAA receptors, which decreased input resistance, depressed burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increased both the amplitude and decay time of inhibitory postsynaptic currents. Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Amytal Sodium
Primary
Amytal Sodium

AUC

ValueDoseCo-administeredAnalytePopulation
56.2 μg × h/mL
120 mg single, intravenous
AMOBARBITAL serum
Homo sapiens
56.07 μg × h/mL
120 mg single, oral
AMOBARBITAL serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
23.8 h
120 mg single, oral
AMOBARBITAL serum
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
40%
AMOBARBITAL plasma
Homo sapiens

Doses

AEs

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Sedative: 30 to 50 mg given 2 or 3 times daily. Hypnotic: 65 to 200 mg at bedtime.
Route of Administration: Oral
In Vitro Use Guide
To 100mkl of the tissue homogenate were added 50 mkl of [3SS]TBPS (at the appropriate concentration, and made in 1 M NaBr), 50 mkl of 50 mM Tris Citrate buffer (to define total binding) or AMOBARBITAL at 100mkM or 50mkl of 40mkM picrotoxinin (to define nonspecific binding). The mixture was incubated 90 min at 21°C and then filtered over glass-fiber filters (Schleicher and Schuell No. 32). Filters were washed three times with 5 ml 0.9% (w:v) NaC1 equilibrated to 21°C and then counted by liquid scintillation spectrometry.
Substance Class Chemical
Record UNII
G0313KNC7D
Record Status Validated (UNII)
Record Version